ATE518009T1 - Verfahren zur diagnose und behandlung von herz- kreislauf-krankheiten - Google Patents

Verfahren zur diagnose und behandlung von herz- kreislauf-krankheiten

Info

Publication number
ATE518009T1
ATE518009T1 AT06829110T AT06829110T ATE518009T1 AT E518009 T1 ATE518009 T1 AT E518009T1 AT 06829110 T AT06829110 T AT 06829110T AT 06829110 T AT06829110 T AT 06829110T AT E518009 T1 ATE518009 T1 AT E518009T1
Authority
AT
Austria
Prior art keywords
diagnosis
treatment
cardiovascular diseases
cardiovascular
diseases
Prior art date
Application number
AT06829110T
Other languages
English (en)
Inventor
Detlef Kozian
Matthias Herrmann
Thomas Leeuw
Wilfried Renner
Winfried Maerz
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of ATE518009T1 publication Critical patent/ATE518009T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06829110T 2005-12-06 2006-11-23 Verfahren zur diagnose und behandlung von herz- kreislauf-krankheiten ATE518009T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05026569A EP1795609A1 (de) 2005-12-06 2005-12-06 Verfahren zur Diagnose und Behandlung von kardiovaskulären Krankheiten
PCT/EP2006/011220 WO2007065562A1 (en) 2005-12-06 2006-11-23 Method for the diagnosis and treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
ATE518009T1 true ATE518009T1 (de) 2011-08-15

Family

ID=35994653

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06829110T ATE518009T1 (de) 2005-12-06 2006-11-23 Verfahren zur diagnose und behandlung von herz- kreislauf-krankheiten

Country Status (13)

Country Link
US (2) US8071297B2 (de)
EP (2) EP1795609A1 (de)
JP (1) JP2009518018A (de)
KR (1) KR20080080527A (de)
CN (1) CN101326291A (de)
AR (1) AR056831A1 (de)
AT (1) ATE518009T1 (de)
AU (1) AU2006322316B2 (de)
BR (1) BRPI0619479A2 (de)
CA (1) CA2632586A1 (de)
IL (1) IL191887A0 (de)
TW (1) TW200741011A (de)
WO (1) WO2007065562A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5714692B2 (ja) * 2010-03-23 2015-05-07 イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングImba−Institut Fuermolekulare Biotechnologie Gmbh Iii型分泌機構の阻害剤の同定方法
CN104090094A (zh) * 2013-05-28 2014-10-08 长兴化学工业股份有限公司 生物医学装置
US20190113520A1 (en) * 2016-03-31 2019-04-18 Discerndx, Inc. Biomarker Database Generation and Use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
WO1997035564A1 (de) 1996-03-25 1997-10-02 Lts Lohmann Therapie-Systeme Gmbh Transdermales therapeutisches system mit geringer applikationsdicke und hoher flexibilität sowie herstellungsverfahren
JP2000507544A (ja) 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 痛みの治療方法
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
JP2004512014A (ja) * 2000-05-18 2004-04-22 学校法人日本大学 虚血状態の検査方法
US20030211525A1 (en) * 2001-08-27 2003-11-13 Walker Michael G Genes expressed in the cell cycle
US20050107386A1 (en) * 2003-11-19 2005-05-19 Rama Krishna Narla Methods of treating diseases and disorders by targeting multiple kinases
EP2186913B1 (de) * 2003-11-26 2016-02-10 Celera Corporation Mit kardiovaskulären Erkrankungen und dem Ansprechen auf Medikation in Zusammenhang stehende Genpolymorphismen, Methoden zu deren Nachweis und deren Verwendung

Also Published As

Publication number Publication date
WO2007065562A1 (en) 2007-06-14
AU2006322316A1 (en) 2007-06-14
JP2009518018A (ja) 2009-05-07
EP1795609A1 (de) 2007-06-13
TW200741011A (en) 2007-11-01
AU2006322316B2 (en) 2011-11-03
KR20080080527A (ko) 2008-09-04
AR056831A1 (es) 2007-10-24
US8071297B2 (en) 2011-12-06
US20090239218A1 (en) 2009-09-24
EP1960543B1 (de) 2011-07-27
CN101326291A (zh) 2008-12-17
EP1960543A1 (de) 2008-08-27
US20120065078A1 (en) 2012-03-15
CA2632586A1 (en) 2007-06-14
BRPI0619479A2 (pt) 2011-10-04
IL191887A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
EP1991274A4 (de) Verfahren zur behandlung, prophylaxe und diagnose von knochenerkrankungen
EP1896083A4 (de) Verfahren zur behandlung von pompe-krankheit mit 1-desoxynojirimycin und derivaten
EP2029743A4 (de) Verfahren zur diagnose und behandlung von schwangerschaftskomplikationen
EP1945754A4 (de) Zusammensetzungen und verfahren zur behandlung und diagnostizierung von krebs
DE602006019753D1 (de) Verfahren und gerät zur behandlung von aneurysmen der a. thoracica
EP2041317A4 (de) Mikro-rna-basierte verfahren und zusammensetzungen zur diagnose und behandlung von erkrankungen in zusammenhang mit darmkrebs
EP1916964A4 (de) Implantate und verfahren zur behebung, ersetzung und behandlung von gelenkkrankheiten
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EP2141989A4 (de) Zusammensetzungen und verfahren zur vorbeugung und behandlung von suchtkrankheiten
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP1701664A4 (de) System und verfahren zur behandlung von gewebe
EP2054047A4 (de) Verfahren zur behandlung von akutem akustischem trauma
EP1799705A4 (de) Antigenkomplex zur diagnose und behandlung von porphyromonas-gingivalis-infektion
DE602006006354D1 (de) Pinolensäure zur Behandlung von Übergewicht
EP3769718C0 (de) Vorrichtung zur behandlung von darmerkrankungen
EP1550462A4 (de) MITTEL ZUR BEHANDLUNG ODER PRûVENTION VON NIERENERKRANKUNGEN UND VERFAHREN ZUR DIAGNOSE VON NIERENERKRANKUNGEN
EP1869212A4 (de) Verwendung von id4 zur diagnose und behandlung von krebs
EP2099446A4 (de) Verfahren zur behandlung von entzündlicher darmerkrankung
EP1812588A4 (de) Anomalitäten von phosphatase 2a (pp2a) zur diagnose und behandlung von morbus alzheimer
EP1709421A4 (de) Verfahren zur diagnose und prognose von krebserkrankungen epithelialer genese
EP1651237A4 (de) Verfahren zur behandlung von dermatologischen erkrankungen
DE60333195D1 (de) Verfahren zur diagnose des myokardinfarktrisikos
EP1791423A4 (de) Zusammensetzungen und verfahren für die behandlung von hyperproliferativen hautkrankheiten
EP1919290A4 (de) Verfahren und produkte zur behandlung von krankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties